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Abstract This review highlights the design principles,
progress and advantages attributed to the structural diver-
sity associated with both natural and synthetic multivalent
antimicrobial peptides (AMPs). Natural homo- or hetero-
dimers of AMPs linked by intermolecular disulﬁde bonds
existed in the animal kingdom, but the multivalency
strategy has been adopted to create synthetic branched or
polymeric AMPs that do not exist in nature. The multi-
valent strategy for the design of multivalent AMPs pro-
vides advantages to overcome the challenges faced in
clinical applications of AMPs, such as: stability, efﬁciency,
toxicity, maintenance of activity in high salt concentrations
and under physiological conditions, and importantly over-
coming bacterial resistance which is currently a leading
health problem in the world. The multivalency strategy is
valuable for moving multivalent AMPs toward clinical
applications.
Keywords Antimicrobial peptides (AMPs)  Multivalent
effect  Multivalent antimicrobial peptides  Structural
diversities
Introduction
As the time for the development of resistance to antibiotics
by microorganisms continues to decrease, the need to
identify and develop new molecules that can overcome the
limitations of the present drugs is urgent. Naturally cationic
antimicrobial peptides (AMPs) including defensins, which
constitute an important component of the innate immune
response of most animal species to microbial infections
have been considered as a template for the development of
new antibiotics due to their unique mechanism of action and
that these molecules will have combat antibiotic resistance
by microorganisms. (Boman 1995, 2003; Hancock 1997;
Zasloff 2002) The world-wide developmental pipeline of
new antibiotics has narrowed due to the issues of resistance
and the academic community has entered into this void.
Some sequence mutation and subsequently structural
changes of the natural antimicrobial peptides have been
engineered into new molecules which have partially over-
come the practical challenges of AMPs for therapeutic use.
As a new generation of prospective antibiotics, AMPs offer
a broad-spectrum antimicrobial activity with an attractive
evolutionary property of action like that of the naturally
occurring peptides so that bacteria may ﬁnd it difﬁcult to
develop resistance (Hancock and Chapple 1999; Giuliani
et al., 2007; Zasloff 2002). However, in clinical applica-
tions, the challenges for AMPs have been (i) toxicity, which
is due to their relatively high minimum inhibitory concen-
tration (MIC) or high dosages that are needed, the low
selectivity for bacterial cell membrane and their antimi-
crobial activity being reduced in the presence of salts under
physiological conditions, (ii) the short half-life in vivo due
to rapid proteolytic cleavage, and (iii) stimulation of an
immune response. An approach of targeting mucosal sur-
faces in topical application may overcome some of these
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DOI 10.1007/s10989-010-9230-zissues (Hancock 1999). Other strategies that have been used
in the face of these challenges include the introduction of D-
or other unnatural amino acids into AMPs (Dooley et al.
1994; Welch et al. 2007; Porter et al. 2000) and small
organic molecule- or foldamer- or polymer- based antimi-
crobial peptide mimics (Savage 2002a, b; Scott et al. 2008;
Liu et al. 2004; Tew et al. 2002, 2010). The design of
multivalent AMPs by conjugation of several or decades of
copies of a peptide monomer to scaffold molecules via
naturally occurred intermolecular disulﬁde bridges or
unnatural scaffold linkers has overcome some of the prob-
lems posed by natural AMPs. The purpose of this review is
to highlight the progresses on rational design of multivalent
AMPs in addressing these issues.
Design Principles for Multivalent Antimicrobial
Peptides
Multivalent/polyvalent interactions, as deﬁned by White-
sides, are multiple simultaneous bindings between two
biological entities (Mammen et al. 1998). These multivalent
interactions prevail in biological system. Multivalent
strategy is originally based on these multivalent interac-
tions, which has implications for design and use of multi-
valent ligands and inhibitors. Through the simultaneous
recognition of multiple binding sites multivalent ligands
can greatly enhance binding ability by several orders of
magnitude in some cases (Rao et al. 1998; Schaschke et al.,
2001; Proﬁt et al. 1999) Covalently attaching bioactive
compounds to a scaffold or core molecule has proven to be a
successful strategy to greatly enhance the afﬁnity of espe-
cially weak carbohydrate ligands to bind to bacteria toxins
(Zhang et al. 2002; Kitov et al. 2000; Pukin et al. 2007) and
bacterial surfaces (Pieters 2007) The development of mul-
tivalent antibiotics (vancomycin) as a potential therapeutic
agent against infections caused by drug resistant microbes
such as methicillin-resistant staphylococcus aureus
(MRSAs) is well documented, (Li and Xu 2005) and it
shows the effectiveness of the multivalent strategy for the
design of more effective anti-microbials. Multivalent AMPs
can be formed by covalently linking to a scaffold or another
core molecule. These multivalent AMPs have been shown
to have advantages over their monomeric forms, such as
enhanced membrane pore formation (Arnusch et al. 2007),
improved antimicrobial activity (Liu et al. 2006), the ability
to maintain good antimicrobial activity under physiological
conditions (100–150 mM or high-salt conditions) (Tam
et al. 2002; Campopiano et al. 2004), improved stability
against protease degradation (Tam et al. 2002; Dewan et al.
2009; Young et al. 2009; Falciani et al. 2007; Pini et al.
2008) and low or no cytotoxicity (Kolar et al. 2010;
McDermott et al. 2010).
Several AMPs units have been covalently linked toge-
ther in the same molecule, i.e. dendritic AMPs, in which
peptide units are covalently linked to scaffolds or a core
molecule. The individual units may act in concert to yield
enhanced properties such as improved potency or improved
speciﬁcity against a target membrane. Such multivalent
effects have been achieved by linking several copies of the
monomeric form of an AMP to a scaffold that apparently
makes AMP units work together in the formation of a pore
in a membrane (Arnusch et al. 2007). Thus the topic of
multivalent AMPs has many different aspects such as unit
length of a sequence, (Pieters et al. 2009) biological
applications (Pini et al. 2008), as well as the structural
diversities of naturally occurring and synthetically pro-
duced multivalent AMPs which will be discussed in this
review.
Structural Diversities of Multivalent AMPs
The chemical structures of multivalent AMPs vary greatly
from naturally occurring or synthetic intermolecular
disulﬁde linked dimers, to synthetic multivalent forms of
AMPs, such as the covalently branched/dendrimeric AMPs
(Tam et al. 2002; Arnusch et al. 2007) and polymeric
AMPs (Liu et al. 2006; Kolar et al. 2010).
The Naturally Occurring or Synthetic
Intermolecular Disulﬁde Linked
Homo- and Hetero-Dimers of AMPs
Bacteria produce proteases and peptidases that hydrolyze
and inactivate the antibiotics which is also a common
mechanism for bacterial inactivation of AMPs (Peschel and
Sahl 2006). A hallmark of several naturally occurring cat-
ionic antimicrobial peptides is the presence of pairs of
disulﬁde bonds. It has been shown that the disulﬁde bonds
convey peptide resistance against proteolytic degradation.
However, the intramolecular disulﬁde bonds are not essen-
tialforantimicrobialpropertiesofdefensins(Maemotoetal.
2004; Rozek et al. 2003; Wu et al. 2003; Liu et al. 2008).
While several naturally occurring antimicrobial peptides
contain 3 or 2 pairs of rigid intra-molecular disulﬁde bonds,
peptidesthatarelinkedbyinter-moleculardisulﬁdebondare
uncommon. Recently, a number of molecules with inter-
moleculardisulﬁdebondscreatinghomo-andhetero-dimers
have been reported (Yomogida et al. 1996; Batista et al.
2001; Hornef et al. 2004). In addition, since the intermo-
lecular disulﬁde bond could reinforce the activity of two
individual chains, the antimicrobial activities of several
synthetic intermolecular disulﬁde linked dimers have been
examined.Inthissection,wewillhighlighttheantimicrobial
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well as synthetic intermolecular disulﬁde bonds.
Yomogida et al. (1996) reported the ﬁrst cationic anti-
microbial peptide (CAP11) with an intermolecular disul-
ﬁde bond isolated from Guinea pig neutrophils granules.
CAP11 contains two identical chains that are rich in basic
amino acid residues (8 arginine and 9 lysine per chain) and
linked through Cys41 (Table 1). CAP11 has potent anti-
microbial activity against both Gram-positive and Gram-
negative bacteria and the activity was not altered by the
presence of 150 mM NaCl. CAP11 was also active against
retroviruses. The S-pyridyl ethylated monomer also
showed comparable antimicrobial activity compared to its
dimer (Okuda et al. 2006). However, the dimer had a
two fold increase in LPS-binding afﬁnity compared to
the monomer. Lee et al. (2001) reported a homodimer
(dicynthaurin) isolated from hemocytes of the tunicate,
Halocynthia aurantium. Dicynthaurin contains two identi-
cal chains with an amidated C-terminus. Antimicrobial
assays suggested that the dimer and the S-carboxymethy-
lated monomer were equally effective against Gram-posi-
tive and Gram-negative bacteria. In the presence of
100 mM NaCl, 5-10 fold decrease in antimicrobial activity
was observed for both the dimer and monomer. However,
the monomer was less haemolytic than the dimer.
Batista et al. reported the ﬁrst puriﬁcation, structural and
functional characterization of a heterodimeric peptide dis-
tinctin, from skin extracts of the tree-frog Phyllomedusa
distincta. (Batista et al. 2001) Distinctin contains 22-(chain
A) and 25-(chain B) amino acid residues and it showed
marked antimicrobial activity against Gram-positive and
Gram-negative bacteria, comparable to conventional anti-
biotics (Table 1). The individual chains showed low anti-
microbial activity (Dalla Serra et al. 2008). Synthetic
homodimers of two chains (i.e., A–A and B–B), however,
had comparable antimicrobial activity with that of the
heterodimer. These results clearly reveal the improvement
in antimicrobial activity of moderately active peptides
through intermolecular disulﬁde bonding. Interestingly, it
has been shown that distintin forms a non-covalent dimer at
pH 6.8 that exists as a compact bundle of four helixes. This
full parallel four-helix structure confers excellent stability
([6 h) against proteolytic enzymes such as trypsin, chy-
motrypsin, and subtilisin (Raimondo et al. 2005). However,
both the monomeric chains A and B existed as a monomer
and were completely degraded by these enzymes. Thus it
was suggested that the covalent association of the two
chains improves the antimicrobial activity and the non-
covalent association protects against proteolytic degrada-
tion (Raimondo et al. 2005). Solid state NMR structural
studies of distinctin in model lipids indicated that distinctin
refolds from a compact four helix structure into a more
open two helix structure (Resende et al. 2009). The
enhanced antimicrobial activity was attributed to this open
structure wherein the helix formed by chain B anchors the
dimer in the membrane interface whereas the chain A
interacts weakly with the bilayer.
Wang et al., reported the heterodimer from hemocytes
of tunicate, Halocynthia aurantium (Jang et al. 2002).
Halocidin contains two chains, a 18 residue leucine rich
peptide connected intermolecularly through cys18 to a 15
residue peptide which lacks the ﬁrst three N-terminus
residues of the 18 residue chain. The antimicrobial activity
of halocidin, the 18 and 15 residue chain monomers, and
their corresponding homodimers were investigated. The 15
residue monomer and its homodimer showed poor anti-
microbial activity. However halocidin, 18 redidue chain
monomer, and its homodimer (di18Hc) exhibited excel-
lent antimicrobial activity against multi-drug resistant
P. aeruginosa and methicillin-resistant S. aureus. The
antimicrobial activity of di18Hc against a number of clin-
ical isolates was investigated in the presence of monovalent
and divalent cations (Jang et al. 2003). The homodimer
retained its activity in the presence of up to 300 mM NaCl.
However, addition of MgCl2 decreased the activity sub-
stantially: about 4 fold decrease in activity was observed at
5 mM MgCl2 against MRSA while the activity was lost
against multi-drug resistant P. aeruginosa.
The reported presence of a number of covalent homo-
and hetero-dimers in mouse intestinal tissue, known as
cryptidin-related sequence (CRS) peptides, further extend
the repertoire of naturally occurring disulﬁde-bonded
covalent dimers (Hornef et al. 2004). The antimicrobial
activities of CRS4C-1a peptide sequence in its monomeric
and dimeric forms were investigated (Hornef et al. 2004). It
has been suggested that the homodimer not only exhibited
superior broad spectrum antimicrobial activity but also
killed the bacteria almost instantaneously compared to the
monomer (Table 1). The diversity of covalently linked
homo or hetero dimeric CRS family of antimicrobial pep-
tides, might potentiate an efﬁcient protection of the gas-
trointestinal mucosa from infection with enteric pathogenic
microorganisms. It is likely that covalent dimerization in
vivo is a mechanism for expanding the diversity of this
innate defense system.
Morrison et al. (2002) identiﬁed a new b-defensin
related (Defr1) gene from mouse that is highly expressed in
heart and testis. The matured form contains 34 amino acid
residues and unlike other b-defensins, Defr1 contains odd
number (ﬁve instead of six) cysteine residues. A synthetic
Defr1 peptide, which existed as an intermolecular disul-
ﬁde-linked dimeric form of 34-residue monomer, exhib-
ited antimicrobial activity against Gram positive bacteria
(S. aureus), and Gram negative bacteria (P. aeruginosa,
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123Table 1 Antimicrobial properties of intermolecular disulﬁde linked homo-/hetero dimers
Peptides  Amino acid sequence  Average 
Antimicrobial 
activity (μ μM) against 
Reference 
G
+ 
pathogens 
G
- 
pathogens 
CAP 11 
(Monomer)  
GLRKKFRKTRKRIQKLGRKIGKTGRKVWKAWREYGQIPYPCRI
(C
41 is S-pyridyl ethylated) 
- 0.1  Okuda et al. 2006 
CAP 11  GLRKKFRKTRKRIQKLGRKIGKTGRKVWKAWREYGQIPYPCRI
GLRKKFRKTRKRIQKLGRKIGKTGRKVWKAWREYGQIPYPCRI
 
0.09  0.09  Yomogida et al. 
1996  
Cynthaurin  ILQKAVLDCLKAAGSSLSKAAITAIYNKIT-NH2  N/A N/A
a Lee  et al. 2001 
di 
Cynthaurin 
 ILQKAVLDCLKAAGSSLSKAAITAIYNKIT-NH2 
 ILQKAVLDCLKAAGSSLSKAAITAIYNKIT-NH2 
N/A  N/A
a   
Distinctin  ENREVPPGFTALIKTLRKCKII 
NLVSGLIEARKYLEQLHRKLKNCKV 
23.4  35  Batista et al . 
2001 
A-A 
homodimer 
ENREVPPGFTALIKTLRKCKII 
ENREVPPGFTALIKTLRKCKII 
25.3  38  Dalla Serra et al. 
2008 
B-B 
homodimer 
NLVSGLIEARKYLEQLHRKLKNCKV 
NLVSGLIEARKYLEQLHRKLKNCKV 
21.7  32.5   
Chain A      ENREVPPGFTALIKTLRKCKII  50.7 76  
Chain B  NLVSGLIEARKYLEQLHRKLKNCKV  38 65   
Halocidin   WLNALLHHGLNCAKGVLA 
    ALLHHGLNCAKGVLA 
N/A  N/A  Jang et al. 2002 
di-18Hc   WLNALLHHGLNCAKGVLA 
 WLNALLHHGLNCAKGVLA  
0.8  <0.26  Jang et al. 2003  
di-15Hc   ALLHHGLNCAKGVLA 
 ALLHHGLNCAKGVLA 
>21.2  >21.2    
Defr1  [DPVTYIRNGGICQYRCIGLRHKIGTCGSPFKCCK]2  1.1  0.9  Campopiano et al. 
2004 
Defr1_Y5C   DPVTCIRNGGICQYRCIGLRHKIGTCGSPFKCCK  27 20.1  Campopiano et al. 
2004 
CRS4C-1a 
dimer 
[LQDAALGWGRRCPQCPRCPSCPSCPRCPRCPRCKCNPK]2 1.2  2.1  Hornef et al. 2004 
CRS4C-1a 
monomer 
LQDAALGWGRRCPQCPRCPSCPSCPRCPRCPRCKCNPK  2.1 6.3   
bis-LLP1  RVIEVVQGACRAIRHIPRRIRQGLERIL 
RVIEVVQGACRAIRHIPRRIRQGLERIL 
0.75  2  Tencza et al. 1999
LLP1  RVIEVVQGACRAIRHIPRRIRQGLERIL  12 1.5   
bis- 
Anaglogue 5 
RVIRVVQGACRAIRHIPRRIRQGLRRIL 
RVIRVVQGACRAIRHIPRRIRQGLRRIL 
0.75  2   
Anaglogue 5  RVIRVVQGACRAIRHIPRRIRQGLRRIL  1 2 
bis-magG3C  GICKFLHSAKKFGKAFVGEIMNS 
GICKFLHSAKKFGKAFVGEIMNS 
12  1.5 
magG3C  GICKFLHSAKKFGKAFVGEIMNS  48 1.5 
bis-TL1  RVIRVVQGACRAIRHIPRRIR 
RVIRVVQGACRAIRHIPRRIR 
1.5  1.25 
TL1  RVIRVVQGACRAIRHIPRRIR  12 2 
Maganin 
(F12W, 
N22C) dimer 
GIGKFLHSAKKWGKAFVGEIMCS-NH2
GIGKFLHSAKKWGKAFVGEIMCS-NH2
-  1  Dempsey et al. 
2003 
Maganin 
(F12W,N22C)
GIGKFLHSAKKWGKAFVGEIMCS-NH2 - >5 
Sushi (S3)  HAEHKVKIGVEQKYGQFPQGTEVTYTCSGNYFLM 
HAEHKVKIGVEQKYGQFPQGTEVTYTCSGNYFLM 
-  0.016  Yau  et al. 2001 
S3-C27S  HAEHKVKIGVEQKYGQFPQGTEVTYTSSGNYFLM  - -  Li et al.  2004 
Bactenecin  RLCRIVVIRVCR  3.7 3.5  Lee  et al. 2008
Parallel 
dimer 
RLCRIVVIRVCR
RLCRIVVIRVCR 
1.8  3.7 
Antiparallel 
dimer 
RLCRIVVIRVCR
 RCVRIVVIRCLR 
1.5  2.5 
PST 13-RK  KKKFPWWWPFKKK-NH2 3.5 2.2   Yang  et al. 2009
diPST 13-
RK 
KKKFPWWWPFKKKC-NH2 
KKKFPWWWPFKKKC-NH2
3.4  1.8 
Tat(W)  GRKKRRQRRRQPQ-NH2 2.0  2.0  Zhu and Shin 
2009 
di-Tat(W)-C  GRKKRRQRRRQPQC-NH2 
GRKKRRQRRRQPQC-NH2
1.0  1.7 
The position and disulphide bond connectivity is shown at the intermolecular disulphide bond (C–C) between two monomers sequences. The
homo-/hetero-dimers with intermolecular disulﬁde bond are shown in rows below with linkage of the intermolecular disulphide bond (C–C) (are
shaded in grey) for the corresponding sequences. The naturally occurring homo/heterodimers are highlighted in bold. (Color ﬁgure online)
N/A
a: MIC data not available
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123E. Coli. and B. cepacia) at a concentration of 50 lg/ml.
The antimicrobial activity of Defr1 against S. aureus,
E. Coli. and B. cepacia was observed to be reduced in
NaCl concentrations of 30–150 mM, but the activity
against P. aeruginosa was independent of salt concentra-
tion. Defr1 was found to have potent activity against
P. aeruginosa, killing 90% of bacteria (LD90)a t1 0lg/ml
(Morrison et al. 2002). Subsequently, the same group
reported structure–activity relationships in defensin dimers
of b-defensin related peptides (Defr1). The ﬁrst description
of a covalently inter-molecular disulﬁde cross-linked dimer
of the defensin family provided further evidence that the
potent antimicrobial activity of a defensin is linked to its
ability to form stable higher order structures, which are
multivalent AMPS (Campopiano et al. 2004). A six cys-
teine variant peptide Defr1 Y5C of Defr1 was synthesized
and its antimicrobial activity was signiﬁcantly lower than
Defr1 (Tables 1 and 2). Mass spectrometry analysis indi-
cated that 34-residue Defr1 formed a covalent dimer as a
mixture of intermolecular disulﬁde-linked dimer isoforms
whereas Defr1 Y5C existed as its monomer with three pairs
of intra-molecular disulﬁde bonds due to the lack of an odd
cysteine residue. In contrast, Defr1 dimers were covalently
stable and were only dissociated into monomers by the
addition of reducing agent. The striking difference in the
antimicrobial activity was attributed to the formation of a
stable covalent dimer of Defr1 through intermolecular
disulﬁde bonds. The oxidized Defr1 Y5C, its reduced form
and the reduced form of Defr1 have similar/comparable
antimicrobial activity due to their very close similarity in
sequence of monomers and being in their monomeric
forms; however, the oxidized Defr1 is a mixture of dimeric
isoforms with two pairs of intra-molecular disulﬁde bonds
and one pair of intermolecular disulﬁde bond and had
signiﬁcantly higher activity than its reduced form (mono-
meric form), Defr1 5YC (in its the oxidized form) and the
reduced form of Defr1 5YC (Tables 1 and 2). Furthermore,
Defr1 (in its covalently dimeric form) almost maintained
activity against Pseudomonsa aeruginosa in the presence
of 25, 50 and 150 mM NaCl and it displayed 100% killing
at 25, 50 mM NaCl, and 84% killing at 150 mM NaCl, and
25% killing even at 300 mM NaCl whereas Defr1 5YC (in
its monomeric form) was almost inactive. The activity of
Defr1 Y5C was extremely salt-sensitive, killing only 10%
of 1 9 10
5 bacteria in the presence of 25 mM NaCl and
being completely inactive at 50 mM NaCl. The striking
difference in antimicrobial activity and salt-insensivity of
the covalent dimer Defr1 compared to Defr1 5YC (the
monomeric form) highlighted the unique contributions of
the covalent dimerization.
Inspired by the synergism when two putative peptides
are combined through a disulﬁde bond, a number of
homodimers have been synthesized. Tencza et al. (1999)
synthesized three homodimers with intermolecular disul-
ﬁde bonds derived from Lentivirus Lytic peptides (LLP1,
Table 1). In addition, these authors also synthesized a
maganin analogue(mag G3C) as a monomer and the
disulﬁde bonded homodimer (Tencza et al., 1999). The
monomers and their corresponding homodimers have
comparable antimicrobial activity against P. aeruginosa.
However, the dimers are more potent against S. aureus than
their corresponding monomers. In addition, the disulphide-
bonded dimers have potent bactericidal activity against
methicillin-resistant S. aureus and vancomycin-resistant
E. faecalis.
Dempsey et al. (2003), reported the synthesis of another
disulﬁde-dimerized magainin analogue (mag N22C) by air
oxidation. The antimicrobial activity of the monomer and
the dimer were tested against Gram-negative pathogens.
The homodimer displayed [*4 fold increase in antimi-
crobial activity compared to the monomer. However, the
dimer induced more haemolysis compared to the monomer.
The increased antimicrobial activity of the dimer was
attributed to the stronger afﬁnity to the negatively charged
membrane.
Yau et al. (2001), examined the antimicrobial properties
of a 34-residue peptide derived from the 3rd domain of
Factor C (S3). The peptide had potent antimicrobial
activity (16 nM) against 30 clinical strains of P. aerugin-
osa. In addition, S3 maintained its antibacterial activity
even at 300 mM NaCl. The work by Li et al. suggested the
importance of an intermolecular disulﬁde bond in the
antimicrobial S3 dimer for binding, disruption, and neu-
tralization of lipopolysaccharide (LPS) (Li et al. 2004).
Recently, improved antimicrobial activity as well as
salt-resistance has been demonstrated for parallel and anti-
parallel homodimers derived from bactenecin (Lee et al.
2008). The parallel dimer exerted a two fold increase in
Table 2 Antimicrobial activity of Defr1 and Defr1 Y5C in the oxi-
dized (dimeric form) and reduced forms (monomeric forms) (red)
Organism Strain MBC
a
Defr1 Defr1
Y5C
Defr1
(red)
Defr1 Y5C
(red)
lg/ml
Gram-negative
P. aeruginosa PAO1 6 50 50 100
E. coli ATCC 25922 8 100 [100 50
Gram-positive
S. aureus ATCC 25923 10 [100 [100 [100
E. fecalis ATCC 292l2 6 100 [100 ND
b
Fungi
C. albicans J2922 3 25 25 50
Data taken from Campopiano et al. (2004)
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whereas its activity was unaltered against Gram-negative
bacteria compared to the monomeric bactenecin. However,
the antiparallel dimer exerted even stronger activity than
the monomer against Gram-positive and the Gram-negative
pathogens. The activity of the monomer against S. aureus
was completely lost and it retained only \40% activity
against E. coli in 150 mM NaCl. The two dimers, on the
other hand, retained their antimicrobial activity in the
presence of 150 mM NaCl.
In an effort to understand the speciﬁcity, Yang et al.
(2009), investigated the effect of dimerization of a trit-
rpticin analogue (PST 13-RK, KKKFPWWWPFKKK-
NH2) formed by intermolecular disulphide bond at the
C-terminus position. Interestingly, the dimer had similar
antimicrobial activity but increased toxicity to eukaryotic
cells. More recently, Zhu and Shin (2009), have investi-
gated the potency and stability of a disulﬁde-linked dimeric
analogue of cell penetrating peptides Tat(W). In addition to
the stronger antimicrobial activity against Gram-positive
bacteria, the disulﬁde-linked dimer showed rapid bacteri-
cidal activity compared to the monomer. However, both the
monomer and dimer were rapidly cleaved by trypsin.
It can be concluded that intermolecular disulﬁde bonds
confer the following properties that may enhance the
therapeutic potential of antimicrobial peptides: (i) high
potency i.e., ability to kill bacterial at lower concentrations
than the monomer; (ii) high selectivity i.e., ability to kill
bacteria with no or low eukaryotic toxicity; (iii) ability to
kill bacteria more rapidly, thereby, controlling bacterial
expansion; (iv) ability to retain the antimicrobial activity
under high salt concentrations, and (v) enhanced resistance
to proteolytic enzymes. Based on the studies mentioned
above, dimerization of a less potent antimicrobial peptide
increased the antimicrobial potency signiﬁcantly whereas a
marginal increase in the activity for an active sequence.
The choice of sequence and position of disulphide bond
plays an important role in determining the therapeutic
potential of these peptides. However, the design and syn-
thesis of homo- or hetero-dimers, tetravalent or other
oligomeric multivalent forms of an AMP based on inter-
molecular disulﬁde linked multimers is limited by the
complexity of the oxidation products (e.g., a mixture of
dimer isomers with different disulﬁde linked patterns),
separation of oxidation products (Campopiano et al. 2004;
Hornef et al. 2004; Wu et al. 2003) and one or two types of
side products due to high oxidization levels involved in the
synthesis (Liu et al. 2009). The concept of multivalent
AMPs based on inter-molecular disulﬁde cross linked
dimer for the increased antimicrobial activity and its anti-
salt property was further supported and proved by Lys-
based branched or polymeric form multivalent AMPs,
which are discussed in the following sections.
Synthetic Unnatural Multivalent AMPs
The unnatural-linked multivalent AMPs have different
chemically structural considerations, depending on the
choice of the scaffold or core molecule. The availability of
a wide variety of scaffold or core molecules provide con-
structs that allows several copies of the peptides to be
appended simultaneously (Fig. 1). Core molecules can be
structurally diverse, ranging from amino acids (e.g., lysine
or glutamic acid dendrimers) (Tam 1988; Sadler and Tam
2002; Tam et al. 2002), simple amino, carboxylic and
hydroxylic cores (Sadler and Tam 2002) or small organic
molecule-based dendrimers (Arnusch et al. 2007), and even
to polymeric chains. (Arimoto et al. 1999; Liu et al. 2006;
Kolar et al. 2010; McDermott et al. 2010). In this section,
we discuss three types of multivalent AMPs and detail their
advantages over disulﬁde-linked dimers.
Design of Dendrimeric or Branched Multivalent AMPs
based on a-Amino Acid Scaffolds
Sadler et al., published a comprehensive review of peptide
dendrimers (Sadler and Tam 2002), which focused on the
types of peptide dendrimers. Applications of peptide
= core or scaffold
= peptide repeat unit
= connecting unit
]
]
n
a
b
c
d
Fig. 1 Schematic representation of dendrimeric/branched and poly-
meric multivalent peptides (a). The dendrimeric/branched core or
scaffold molecules can be Lys or other molecules. One lys for
divalent AMPs, three Lys for tetravalent AMPs and seven Lys for
octavalent AMPs; (a-c) The core or scaffold may contain 2, 3, 4 or 8
connecting units that can be used to create divalent, trivalent,
tetravalent and octavalent AMPs (a–c). d The peptide can be
covalently linked to a polymerizable monomer or poymeric unit to
produce peptide-polymer conjugates
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123dendrimers include use as biomedical diagnostic reagents,
protein mimetics, anticancer and antiviral agents, vaccines
and drug and gene delivery vehicles. The e-amino group of
the lysine and the carboxyl group of the glutamic acid have
been used as a core for the synthesis of multivalent AMPs.
Tam (1988) pioneered the synthesis and study of bioactive
peptides containing a lysine core. a- and e-amino groups of
lysine are used for the generation of two, four, and eight
copies of short peptide sequences (Tam et al. 2002).
Dendrimeric/branched multivalent AMPs can be directly
synthesized by solid phase peptide synthesis (SPPS) via the
use of several double Fmoc Lys. (e.g., 1 Lys for dimer, 3
Lys for tetramer and 7 Lys for octamer) (Fig. 1a). The
synthesis does not need any additional steps for synthesis of
a scaffold or core molecule, which is used to link several
copies of an AMP. This strategy has many advantages
over the corresponding linear analogues such as stability
against proteases (Tam et al. 2002; Bracci et al. 2002; Lozzi
et al. 2003; Falciani et al. 2007; Young et al. 2009; Dewan
et al. 2009) and lack of salt sensitivity, (Tam et al. 2002;
Dewan et al. 2009) the two important criteria that limit the
therapeutic potential of AMPs. Pini et al. (2008) and Pieter
et al. (2009) have partially reviewed some examples
developed by this method, which focused on different
biological functions and membrane permeabilization,
respectively. Here we would like to summarize progress
with this type of Lys-based dendrimeric or branched mul-
tivalent AMPs.
In their ﬁrst report, Tam et al. (2002) examined the
effects of increasing the number of branches and peptide
sequences on antimicrobial and haemolytic activity. A four
residue RLYR and an octapeptide RLYRKVYG sequences
that represent the topological motifs of the tachyplesin-1
were appended to mono, tri, and hepta lysine cores
to produce divalent, tetravalent, or octavalent peptides,
respectively. (Figs. 1a, 2 compares the effect of increasing
the repeating units of linear sequence/branch numbers on
therapeutic index (deﬁned as the effective concentration
required to cause 50% haemolysis divided by geometric
mean minimum inhibitory concentration). For linear pep-
tides, a plateau is observed after 2 or 3 repeat units whereas
for branched peptides the value increases exponentially
with increasing branches.
The use of AMPs in vivo has been largely limited by
their short half-lives, since peptides are susceptible to
endogenous proteases and peptidases. In an attempt to
compare the stability of linear and branched peptides, Tam
et al. examined the antimicrobial activities of these pep-
tides in the presence of trypsin (Tam et al. 2002). The
linear peptide lost their antimicrobial activity within the
ﬁrst few minutes after digestion whereas the tetravalent
RLYR retained *80% antimicrobial activity even after
24 h. Similar results were obtained for the tetravalent and
octavalent forms of RLYRKVYG (*65% activity after
24 h). Thus, branching improves the proteolytic resistance,
the shorter sequence being more resistant compared to the
longer one.
Kallenbach’s group has conducted an extensive study
with a branched tetramer (RW)4D [(RW)4K2K] in which
four copies of sequence (RW) were linked to a Lys scaffold
(Fig. 3) (Liu et al. 2007; Hou et al. 2009; Young et al.
2009). In a demonstration, Liu et al. (2007), examined the
effects of increasing the repeat units for a dipeptide (RW)
on antimicrobial and haemolytic activity. Similar to the
results obtained by Tam et al. a plateau was observed
beyond a trimer for the linear series as well. However,
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Fig. 2 Relationship between therapeutic index with increasing num-
ber of repeats for linear and branched peptides. Note that the
therapeutic index increases several fold for branched peptide s
compared to linear peptides. Data taken from Tam et al. (2002)
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Fig. 3 Structure of tetramer (RW)4D. Redrawed structure from Liu
et al. (2007)
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123(RW)4D had about 10 fold increase in therapeutic index
compared to the linear tetramer. These studies suggested
that increasing the number of repeats through branching
ampliﬁes the antimicrobial properties without affecting the
toxicity. In addition, the tetramer (RW)4D inhibits bacterial
growth in both planktonic and bioﬁlm states. Live/Dead
cell assays revealed that most bacteria in a preformed
bioﬁlm lose viability after treatment with this peptide and
this result is in marked contrast to the existing report that
antimicrobial peptides are ineffective against mature bac-
terial bioﬁlms (Hou et al. 2009).
Tetramer (RW)4D displays enhanced activity against
multi-drug resistant (MRD) bacteria and shows protease
stability. Young et al. used similar assay and compared the
stability of tetramer (RW)4D with indolicidin (Young et al.
2009). After indolicidin was treated with 100 nM trypsin
for 1 h or 1 lM trypsin for 2–5 min, about 25–30%
reduction in the antimicrobial activity was observed for
indolicidin peptide whereas the tetramer did not lose the
activity even after 24 h. By contrast, the antibacterial
activity of (RW)4D was unaltered even at high trypsin
concentration (up to 1 lM) over various time intervals (up
to 24 h) (Young et al. 2009).
Our group has recently reported the structural parame-
ters for antimicrobial activity, human epithelial cell cyto-
toxicity and killing mechanism of synthetic monomers
and branched dimer derived from the C-terminus region
of hBD3 (e.g., V2-monomer: RGRKVVRRKK) and
V2-dimer: (RGRKVVRR)2KK)) (Zhou et al. 2010). The
branched V2-dimer showed potent broad-spectrum anti-
microbial activity whereas the V2-monomer was only
active against P. aeruginosa. V2-dimer showed higher
antimicrobial activity against P. aeruginosa ATCC 9027
(Log Reduction: 2.82; almost equals to 99.9% bacteria
being killed at 2.74 lM) compared to V2-monomer (Log
Reduction: 2.02, equals to 99% bacteria being killed at
4.8 lM). Using ﬂuorescence correlation spectroscopy
(FCS), signiﬁcant aggregation and some leakage of rho-
damine dye were observed with anionic lipids POPG with
V2-monomer at the concentration of 10 lM and no sig-
niﬁcant aggregation or disruption of vesicles was observed
for V2-monomer and V2-dimer tested against POPC.
V2-dimer induced more leakage and aggregation than the
monomeric form. V2-dimer is the most effective antimi-
crobial peptide, with aggregation of POPG vesicles
observed at concentrations as low as 1 lM.
In a systematic study on the effect of covalent dimer-
ization on antimicrobial activity, Dewan et al. reported
antimicrobial action of prototypic amphiphilic cationic
decapeptides (Ac-G-X-R-K-X-H-K-X-W-A-NH2, X was
didehydrophenylalanine for monomer DFm, a-aminoiso-
butyric acid for Um, or phenylalanine for Fm) and their
branched dimers (Dewan et al. 2009) (Table 3). Among
these monomers, only DFm was modestly anti microbial
(MICs of 110 lM( E.coli) and 450 lM( S. aureus). Inter-
estingly, a linear dimer of DFm, viz. (DFm)2 turned out to
be highly potent against E. coli (MICs of 2 lM and min-
imum bactericidal concentration (MBC) of 2 lM) and
modestly potent against S. aureus (MICs of 20 lM and
MBC of 20lm). In contrast, the branched dimer of phen-
ylalanine (Fd) and didehydrophenylalanine (DFd) showed a
strong increase in potency, the latter was found to be a
potent antimicrobial against both E. coli (MIC of 2.5 lM)
and S. aureus (MIC of 5 lM) and had about 9 fold increase
in anti S. aureus activity compared to the Fd substitution.
In addition, DFd exhibited highest afﬁnity for LPS, rapid
bacterial killing, no haemolytic activity and excellent
proteolytic resistance against trypsin. Thus studies with
branched dimers of Fm and Um have indicated that cova-
lent dimerization represents a scaffold for potentiation of
antimicrobial peptides. Furthermore, these authors have
also examined the proteolytic stability of the peptides in
the monomeric form (i.e., DF, F, and U) in the presence of
cytosolic extracts, trypsin, and chymotrypsin. The phen-
ylalanine and a-aminobutyric acid analogues were degra-
ded readily whereas the didehydrophenylalanine remained
intact. Thus, resistance against proteolysis in branched
peptides could be enhanced by appropriate substitution of
unnatural amino acids.
An elegant demonstration of the structure–activity rela-
tionshipofbranchedpeptideshasbeenreportedbyPinietal.
(2005). These authors assembled a 10 residue peptide
QKKIRVRLSA on a tetrabranched lysine scaffold (M6)
and examined the antimicrobial activity. M6 displayed
potent antimicrobial activity against several Gram-negative
pathogens but showed poor activity against Gram-positive
pathogens.Toassesstheactivityspectrum,alaninescanning
was performed wherein each residue in the QKKIRVRLSA
sequence was replaced with an alanine residue and analyzed
for antimicrobial activity (Fig. 4). The results indicated that
K2A, I4A, V6A, and L8A substitutions lead to a profound
decrease ([15 fold reduction) in the antimicrobial activity
whereas other residues affected the activity marginally
suggesting the importance of bulky hydrophobic side chains
in the branched peptides. To investigate the lysine-arginine
disparity, these authors replaced each of the lysine 2
and 3 with arginine. While K2R replacement increases the
activity slightly K3R and the double replacement (i.e. K2R,
K3R) lead to 8 or 9 fold decrease in antimicrobial activity
(Table 2). Furthermore, shortening the sequence by
removing the Q1 resulted in 3 fold decrease in the antimi-
crobial activity. These results clearly showed that M6 was
optimized for antimicrobial activity against Gram-negative
bacteria.
Recently, two independent studies compared the antimi-
crobialpropertiesofabrancheddimerandanintermolecular
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123Table 3 Antimicrobial
properties of branched peptides
containing lysine and glutamic
acid core
The branched K/E is highlighted
in represented in italics. The
branched peptides are
highlighted in rows below (in
grey) whereas the linear
peptides are highlighted in rows
above for the corresponding
sequences
a The antimicrobial activity was
at low salt conditions
e g a r e v A e c n e u q e S e d i t p e P
Antimicrobial 
activity (μ μM) 
Reference 
G+ G- 
R4  RLYR
a >500 >500 Tam et al. 2002 
(R4)2 RLYRRLYR
a 3.5 16.9   
(R4)4 RLYRRLYRRLYRRLYR
a 1.1 1.4  
D2R4  (RLYR)2K
a 4.4  4.2 
D4R4  (RLYR)4K2K
a 0.7  0.83 
D8R4  (RLYR)8[K2K]2K
a 0.6  0.5 
R8  RLYRKVYGK
a 37.3 51.6  
D2R8  (RLYRKVYG)2K
a 2.63  6.7 
D4R8  (RLYRKVYG)4K2K
a 0.5  0.8 
D8R8  (RLYRKVYG)8[K2K]2K
a 0.27  0.48 
(RW)4-NH2
a 12 14 Liu et al. 2007 
(RW)4K2K
a 9  2.5  Liu et al. 2007 
M5    [KIRVRLSA]4K2K  not 
active 
10.1  Pini et al. 2005 
M6  [QKKIRVRLSA]4K2K  not 
active 
0.8 
M31  [AKKIRVRLSA]4K2K 3.3 
M32/M4  [QAKIRVRLSA]4K2K 16.3 
M33  [QKAIRVRLSA]4K2K 1.6 
M34  [QKKARVRLSA]4K2K 12.9 
M35  [QKKIAVRLSA]4K2K 4.2 
M36  [QKKIRARLSA]4K2K 12.8 
M37  [QKKIRVALSA]4K2K 3.3 
M38  [QKKIRVRASA]4K2K >12.9 
M39  [QKKIRVRLAA]4K2K 3.6 
M28  [QRKIRVRLSA]4K2K 0.6 
M29  [QKRIRVRLSA]4K2K 6.1 
M30  [QRRIRVRLSA]4K2K  7.5 
PST13-RK  KKKFPWWWPFKKK-NH2  3.5 2.2   Yang  et al. 2009 
di -PST13-
RK-K 
(KKKFPWWPFKKK)2K 2.7  2.1 
Tat(W)  GRKKRRQRRRQPQ-NH2  2.0  2.0  Zhu and Shin 2009 
di-Tat(W)-
K
(GRKKRRQRRRPWQ)2K 1.0  1.0 
Fm  AcGFRKFHKFWA-NH2 > 500  >500  Dewan et al. 2009 
Um AcGURKUHKUWA-NH2 > 500  >500   
ΔFm AcGΔFRKΔFHKΔFWA-NH2 450 110  
(ΔFm)2 AcGΔFRKΔFHKΔFWAAGΔFRKΔFHKΔFWA-
NH2
20 2   
Fd Ac(GFRKFHKFWA)2K 45  3 
ΔFd Ac(GΔFRKΔFHKΔFWA)2K 5  2.5 
Ud Ac(GURKUHKUWA)2K 30  >100 
RLAR  not 
active 
 Khrushcev et al.
2007 
E(RLAR)2 250 
EE2(RLAR)4 12 
KLAR  not 
active 
E(KLAR)2 not 
active 
EE2(KLAR)4]  15 
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123disulﬁdelinkedhomomodimer.Yangetal.(2009)dimerized
a 13 residue peptide, KKKFPWWWPFKKK by cysteine
oxidation and incorporation of branched lysine at the
C-terminusandcomparedtheirantimicrobialpropertieswith
the monomer. While neither of the dimers affected the
antimicrobial activity signiﬁcantly, the therapeutic index
dropped considerably from 47 for the monomer to 2 for the
dimers suggesting a loss in selectivity when the potent
monomer was dimerized. Similar to these studies, Zhu and
Shin (2009) compared the effects of dimerization of a cell
penetrating Tat sequence GRKKRRQRRRPWQ, on anti-
microbial activity. Membrane depolarization assays indi-
cated that both the dimers killed S. aureus rapidly compared
to the monomer. However, monomer, homodimer and
brancheddimerwererapidlycleavedbytrypsinwithinafew
minutes. The two examples showed the antimicrobial
activity and stability of dimers was dependant on monomer
sequences and the locations of dimerization in comparison
with those of dimers mentioned above.
Khrushchev et al. (2007) reported the ﬁrst example of
glutamic acid based dendrimeric peptides and examined
the antimicrobial properties. Divalent and tetravalent cop-
ies of four residue peptides KLAR or RLAR have been
synthesized and their antimicrobial activity was examined
against E. coli. A sharp increase in the anti E. coli activity
was observed for both tetravalent peptides compared to the
divalent analogues.
Based on these observations, lysine scaffold based
multivalent AMPs confers several advantages over mono-
mers, linear peptides or intermolecular disulphide-linked
dimers. These include (i) ease of synthesis i.e., requires
fewer steps than linear analogues and disulﬁde-linked
dimer, (ii) multiple copies can be prepared which is
difﬁcult for the disulphide linked peptides, (iii) high
potency under physiological salt concentration against
broad spectrum of pathogens, (iv) signiﬁcant retention of
activity in the presence of proteolytic enzymes and cyto-
solic extracts.
Multivalent AMPs Formed with a Small Organic
Molecule Scaffold or Core via ‘‘Click Chemistry’’
Arnusch et al. (2007) designed divalent, tetravalent and
octavalent forms of magainin 2 by the use of alkyne
substituted dendrimers based on 3,5-di-(2-aminoethoxy)
benzoic acid repeating units as a core molecule via a
copper-mediated 1-3 dipolar cycloaddition reaction named
‘‘click’’ chemistry. Figure 5 shows structures of dendritic
core molecules (compounds 1–3) and the linkage spacer
(structure 4) between peptides and dendritic core mole-
cules. The dendritic core molecules are covalently linked to
AMPs by a chemo- and regio-selective coupling of an
alkyne moiety of dendritic core molecule to an azide-
functionalized maganin 2 peptide, yielding a 1,4-disub-
stitued 1,2,3-triazole-linking spacer (structure 4) via click
chemistry to prepare multivalent magainin 2 including
divalent, tetravalent and octavalent compounds (Fig. 5).
The authors synthesized multimers with 2, 4, and 8 copies
of maganin 2 and examined the efﬁcacy of these analogues
in releasing carboxy ﬂuorescein dye from model lipids.
Predictably, the dye release potency greatly increased with
number of copies. An enhancement of around 100 fold was
obtained for the tetravalent compound, an enhanced
membrane pore formation action of almost 600-fold was
observed with octavalent magainin 2 (Tables 4 and 5). The
antimicrobial activity of maganin 2 and the multivalent
peptides were evaluated against B. subtilis. The divalent
form of magainin 2 was about 5-times more potent than
magainin 2 and the tetravalent analogue had the same
activity as maganin 2 (Pieters et al. 2009). (When we
calculated their relative potency, unit of MIC was con-
verted from lg/ml into lM.) Thus, contrary to lysine core,
the 3,5-di-(2-aminoethoxy) benzoic acid-based dendritic
core molecules seemed to be less efﬁcient in amplifying the
antimicrobial properties.
Multivalent AMPs Formed by Attaching Peptides
to Reactive Polymer Scaffolds
The principles of multivalency not only can be applied by
attaching several copies of AMPs (less than ten) to a small
molecule scaffold or core (already shown above), but also
can be applied to attaching several copies or even many
copies (several tens or even hundreds) of AMPs to an
active biopolymer and synthetic polymer with several or
numerous repeating units. Hjørringgaard et al. (2009)
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Fig. 4 Effect of alanine substitution on antimicrobial properties of
the tetrabranched peptide, M6. Each vertical bar represents the result
of antimicrobial activity on single alanine substitution in the original
sequence, which is shown on top. Note that alanine replacement of all
hydrophobic residues lead to considerable decrease in antimicrobial
activity whereas replacing charge residues with alanine decreased
moderately (except K2). Data taken from Pini et al. (2005)
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123reported synthesis of templated multimers of AMPs,
in which six copies of antimicrobial peptide alamethicin
were covalently bound to cyclodextrin scaffolds via
‘‘click chemistry’’. Cyclodextrins (CDs) are a family of
compounds made up of sugar molecules bound together in
a ring (cyclic oligosaccharides, including a-, b- and c-CD
with six, seven and eight sugar units, respectively), a
family of naturally occurring biopolymer, which are
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Fig. 5 The chemical structures of alkyne-functionalized 3,5-di-(2-
aminoethoxy) benzoic acid-based dentritic core molecules (com-
pounds 1-3 for divalent, tetravalent and octavalent maganin 2,
respectively) which provide alkyne group for the Cu(I)-catalyzed
alkyne-azide cycloaddition (named ‘‘click chemistry’’) and the
linkage spacer (a 1,4-disubstitued 1,2,3-triazole-linking spacer,
structure 4), which was formed between maganin 2 and dendritic
core molecules by click chemistry. Redrawed structure from Arnusch
et al. (2007)
Table 4 Leakage results for
5(6)-carboxyﬂuorescein from
mixed DOPC/DOPG vesicles
(25 lM, 1/1)
Data taken from Arnusch et al.
(2007)
Compound L50
a (nM) Relative potency
(per peptide)
Molecular
mass (kDa)
Real potency
(ug/ml
)
Octavalent 14 107 (13.4) 22.5 0.31
Tetravalent 130 11.5 (2.9) 11.2 1.49
Divalent 230 6.5 (3.25) 5.48 1.26
Divalent 250 6 (3) 5.48 1.37
Magainin 1500 1 (1) 2.47 3.7
Table 5 Leakage results for
5(6)-carboxyﬂuorescein from
DOPC vesicles (25 lM)
Data taken from Arnusch et al.
(2007)
Compound L50
a (nM) Relative potency
(per peptide)
Molecular
mass (kDa)
Real potency
(ug/ml)
Octavalent 17 255 (73) 22.5 0.38
Tetravalent 22 454 (113) 11.2 0.25
Divalent 250 40 (20) 5.48 1.37
Divalent 370 27 (13.5) 5.48 2.03
Magainin 10000 1 2.47 24.7
Int J Pept Res Ther (2010) 16:199–213 209
123produced from starch by means of enzymatic conversion.
Alamethicin represented one of the antimicrobial peptides,
constructed of 20 residues of which eight were a-amino-
isobutyric acids, Aib. Alamethicin inserts into lipid bilay-
ers via the N-terminus, aggregates and forms voltage-gate
channels, which accounts for its antibiotic activity. CD has
been functionalized with azide groups. Alamethicin has
been synthesized using automated solid phase peptide
synthesis. A linker containing the alkyne group has been
incorporated into the peptide. Then the multimers of anti-
microbial peptide alamethicin were synthesized by cou-
pling of an alkyne group of peptide to the azide groups of
CD scaffolds to form multivalent form of alamethicin.
These multivalent AMPs can be used as model artiﬁcial
channels and will be compared to the monomeric species
in electrophysiological experiments as well as labeling
experiments using NMR spectroscopy, to probe the struc-
ture and function of these channels. Furthermore, the
structures of the artiﬁcial channels can be examined using
NMR in membrance environments.
The emergence of vancomycin-resistant bacteria (e.g.,
vancomycin-resistant Enterococci (VRE); vancomycin-
resistant S. aureus (VRSA)) is of concern clinically and in
hospitals, because vancomycin is the last resort for the
treatment nosocomial infections due to multidrug-resistant
gram-positive bacteria. The hypothesis is that noncovalent
associated dimer of vancomycin plays an important role in
the recognition events of the lipid intermediates. This
hypothesis promoted synthetic chemists to design cova-
lently-linked dimer or multivalent or polymeric forms of
vancomycin (Arimoto et al. 1999; Lu et al. 2007). Arimoto
et al., reported that the ﬁrst multivalent polymer of van-
comycin greatly enhanced its antimicrobial activity against
vancomycin-resistant Enterococci (VRE, VanA and VanB)
(Arimoto et al. 1999; Li and Xu 2005). Polymeric forms of
vancomycin (methanol) show the enhancement 8-63 fold in
potency against VRE with retention of practical MIC val-
ues against S. aureus and Enterococci (Fig. 6; Table 6).
Based on the design principle of poly/multivalent interac-
tions between receptors and ligands, this was a pioneering
method to produce multivalent forms of antibiotics (e.g.,
glycopeptide vancomycin) to overcome the drug resistance
against VRE. It has been shown that the choice of the
linker structure signiﬁcantly affects the antimicrobial pro-
ﬁles of multivalent vancomycin. Subsequently, the same
group designed rigidly-linked vancomycin dimers by the
use of actinocin, a natural previleged scaffolds as linkers of
vancomycin dimers, the in vitro and in vivo data displayed
that the dimers exhibited excellent antimicrobial activities
in the murine infection model and improved their in vivo
efﬁciency against resistant bacteria (Lu et al. 2007).
In another example, Kallenbach’s group designed
polymeric forms of cationic antimicrobial peptide. The
design of polymer-AMPs conjugates were based on the
action mechanism of AMPs (e.g., the formation of trans-
membrane pores) by the application of the design principle
of multivalency. The authors reported that 4-residue pep-
tides (RWRW and RRWW) were linked to the biocom-
patible reactive poly(maleic anhydride) (PMA) to yield
polymeric peptides containing 39–40 monomeric units (Liu
et al. 2006) (Figure 7). Relative to the free peptides, the
polymer-peptide conjugates show a 15- or 10-fold
improvement in IC50 against E. coli and B. subtilis
N
H
H
O O
O
NH
Van
n
Fig. 6 The structures of polymeric form of vancomycin. Redrawed
structure from Li and Xu (2005)
Table 6 Antibacterial activities (MIC, lg/ml) of the monomeric
vancomycin and polymeric vancomycin
Compound S. aureus Enterococci VRE
(VanA)
VRE
(VanB)
Vancomycin 0.2 \0.5 [250 125
Polymeric Van
(emulsion condition)
NA 31 [250 31
Polymeric Van 2.3 2 31 2
Data taken from Arimoto et al. 1999 and Li and Xu 2005
*
X
X X X
X
X X
*
n
= peptide X = carboxymethyl n = 39, 40
Fig. 7 Structure of polymeric AMPs based on 4-residue peptides
(RWRW and RRWW) and a polymaleic anhydrde (PMA) chain.
Redrawed structure from Liu et al. (2006)
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123(Table 7) without provoking more severe hemolysis of red
blood cells. This clearly highlights multivalency or
polyvalency as a useful route to enhance the activity of
antimicrobial peptides with high therapeutic potential for
treating microbial or viral infection (Malamud et al. 2007).
In a conference report, the method of click chemistry
was applied by Cai and McDermott et al. to covalently
conjugate cathelicidin derivatives (LL-37 or LL-25) to
polymerized-liposomes (polydiacetylene, PDA) or ﬂu-
orous polymer surfaces, a 100 fold antimicrobial activity
was achieved with low cytotoxicity (Kolar et al. 2010;
McDermott et al. 2010).
Concluding Remarks
Multivalent forms of antimicrobial peptides or other type
of antibiotics (e.g., glycopeptide vancomycin), have been
discussed, in which several or decades of copies of peptides
were attached to a series of structurally diverse scaffold or
core molecules. One of the advantages for application of
design principle of multivalency lies in the structural
diversity of many types of scaffolds molecules, the control
and the tuning the multivalency. It has been clearly
shown that the choice of scaffold molecules or the linker
structures and the multivalency signiﬁcantly affects the
antimicrobial proﬁles of multivalent AMPs. There is con-
siderable evidence that covalent dimerization or multi-
merization/polymerization of antimicrobial peptides pro-
vides advantages as a strategy to overcome the challenges
of AMPs, such as drug resistance, killing ability, cytotox-
icity and stability) to move them toward potentially clinical
applications. However, the quantitative structure–activity
relationship (QSAR) of multivalent AMPs and the physical
parameters of these multivalent AMPs for the improvement
of their biological functions are still poorly understood on a
molecular level. The design strategy of multivalency was
proved as a useful and practical route to greatly enhance
the activity of antimicrobial peptides with high therapeutic
potential for treating microbial or viral infection.
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